Zydus Cadila receives final approval for Diflunisal Tablets
From USFDA
Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content